Back to search
FDAFDA · Food and drugs·Recall number D-783-2013

Stanozolol (50 mg/ml and 100 mg/ml) Injection, compounded by Olympia Pharmacy, Orlando, FL

Published July 17, 2013 · Recall initiated: May 29, 2013

Summary

FDA records drug Class II recall D-783-2013, published July 17, 2013 and initiated May 29, 2013. Recalling firm: Lowlite Investments, Inc. D/B/A Olympia Pharmacy; Status: Ongoing; Reported quantity: 3; Lot: 50mg/ml = Lots B5727 Exp 8/27/13, and C5708 Exp 9/8/13 // 100,g/ml =Lot C5706 Exp 9/6/13. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lowlite Investments, Inc. D/B/A Olympia Pharmacy
Distributor
Nationwide and PR
Lot
50mg/ml = Lots B5727 Exp 8/27/13, and C5708 Exp 9/8/13 // 100,g/ml =Lot C5706 Exp 9/6/13
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Stanozolol (50 mg/ml and 100 mg/ml) Injection, compounded by Olympia Pharmacy, Orlando, FL recalled?

Yes. FDA published recall D-783-2013 on July 17, 2013. Reported hazard: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit